宁康瑞珠生物制药（珠海）有限公司

Rezubio is a biotechnology company developing next-generation targeted therapeutics for obesity and other diseases using its proprietary Membrane-Anchored Drug Design (MADD) platform. Our membrane-anchored drug design (MADD) platform links a pharmacophore to a membrane-mimicking kinetophore that lodges the molecule in the lipid bilayer, enabling unprecedented control of drug distribution and exceptional specificity for cell-surface targets—taming powerful pharmacophores for precise site of action and unlocking a new class of safer and more effective drugs. To learn how Rezubio’s membrane-anchored drug design platform enables precise tissue targeting and accelerates drug discovery and development, please contact us to explore partnership and business development opportunities. Connect with us: contact@rezubio.com 68 Qianhebei Rd, Unit 1908, Zhuhai, China, 519070。